Italy· 048410017
BEXAROTENE*100 cps molli 75 mg flacone
A bexarotene product containing bexarotene, registered in Italy by CIPLA EUROPE NV, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Bexarotene is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XF03 (bexarotene), each read from that country’s own register.
- This record: Italy
- 8 of them publish a price we can compare per daily dose
Bexarotene · ATC L01XF03
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Bexarotene
- Manufacturer
- CIPLA EUROPE NV
- Country
- Italy (IT)
- ATC code
- L01XF03
- ATC class
- Bexarotene
- Defined daily dose
- 0.54 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic048410017BEXAROTENE*100 cps molli 75 mg flaconeEUR 901.14
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
573 interactions on record for bexarotene.
Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bexarotene · interactions on record
573 records
- 127 severe
- 357 moderate
- 80 minor
- 9 info
Most severe, free to view
- EluxadolineA07DA06severe
- LiraglutidA08AX02severe
- SemaglutidA08AX03severe
- SitagliptinA10BH01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bexarotene in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesbexaroteneActavis Pharma, Inc.
- FinlandBexarotene AmdipharmAmdipharm Limited
- United KingdomBexarotene 75mg capsulesAdvanz Pharma
- NorwayBexarotene AmdipharmAmdipharm Limited
- SpainBEXAROTENO CIPLA 75 MG CAPSULAS BLANDAS EFGCipla Europe N.V.
- SwedenBexarotene Amdipharm 75 mg Kapsel, mjukAmdipharm Limited
- FranceBEXAROTENE CIPLA 75 mg, capsule molleCIPLA EUROPE (BELGIQUE)
- PolandTargretinH.A.C. Pharma
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Bexagia
- Germany · Bexaroten Cipla
- Denmark · Bexarotene
- Spain · Bexaroteno Cipla
- Finland · Bexarotene Amdipharm
- France · Bexarotene Cipla
- United Kingdom (Northern Ireland) · Bexarotene Genus Pharmaceuticals Ltd.
- Iceland · Targretin
- Liechtenstein · Targretin
- Norway · Bexarotene Amdipharm, Targretin
- Sweden · Bexarotene Amdipharm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7f32f620-0d05-48ed-b7b7-48fafa0eee73 GET /v1/drugs/7f32f620-0d05-48ed-b7b7-48fafa0eee73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 901.14,
"source": "aifa",
"currency": "EUR",
"strength": "BEXAROTENE 75MG 100 UNITA' USO ORALE",
"substance": "Bexarotene",
"equivalence_group": "TTA",
"transparency_flag": null
}See everything about bexarotene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.